Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6421
    -0.0004 (-0.07%)
     
  • OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD

    2,406.70
    +8.70 (+0.36%)
     
  • Bitcoin AUD

    99,703.05
    +3,557.98 (+3.70%)
     
  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     
  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     
  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Agilent (A) Gears Up for Q4 Earnings: What's in the Cards?

Agilent Technologies A is set to report fiscal fourth-quarter 2019 results on Nov 25. In the last reported quarter, the company delivered a positive earnings surprise of 5.56%.

For the fiscal fourth quarter, the Zacks Consensus Estimate for earnings has remained stable at 86 cents per share over the past 30 days. This indicates growth of 6.2% from the year-ago reported figure.

Notably, the consensus mark for revenues is pegged at $1.33 billion, implying growth of 2.6% from the year-ago reported figure.

Let’s see how things have shaped up for this announcement.

Agilent Technologies, Inc. Price and EPS Surprise

 

Agilent Technologies, Inc. Price and EPS Surprise
Agilent Technologies, Inc. Price and EPS Surprise

Agilent Technologies, Inc. price-eps-surprise | Agilent Technologies, Inc. Quote

ADVERTISEMENT

Strength in ACG Segment to Drive Revenues

Revenues are expected to have increased in the to-be-reported quarter, driven by strength in services and consumables across all geographical regions served. The Zacks Consensus Estimate for this segment’s revenues is currently pegged at 463 million.

Strength in DGG & LSAG

The company expects strong revenues from Diagnostics and Genomics Group (DGG) in the to-be-reported quarter, driven by growth in pharma, and strength in genomics and NASD products.

Also, the Life Sciences & Applied Markets Group (LSAG) segment is likely to have generated solid revenues in the quarter to be reported, driven by strong performances of chemical and energy, as well as pharma and environmental markets.

The Zacks Consensus Estimate for DGG & LSAG is currently pegged at 267 million and 597 million, respectively.

The company’s focus on aligning investments toward more attractive growth avenues and innovative product launches is expected to have been a positive for the quarter.

What Our Model Says

Our proven model does not conclusively predict an earnings beat for Agilent this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here as you will see below.

Earnings ESP: The company has an Earnings ESP of -0.78%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Currently, Agilent has a Zacks Rank #3.

Stocks That Warrant a Look

Here are a few stocks worth considering, as our model shows that these have the right combination of elements to deliver an earnings beat in the upcoming releases.

Pinduoduo, Inc. PDD has an Earnings ESP of +25.00% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

CSX Corporation CSX has an Earnings ESP of +0.50% and a Zacks Rank #3.

Momo Inc. MOMO has an Earnings ESP of +3.94% and a Zacks Rank #3.

More Stock News: This Is Bigger than the iPhone!                  

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CSX Corporation (CSX) : Free Stock Analysis Report
 
Momo Inc. (MOMO) : Free Stock Analysis Report
 
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
 
Pinduoduo Inc. Sponsored ADR (PDD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research